Determining magnitude of benefit from poly(ADP-ribose) polymerase inhibitors in prostate cancer

Abstract

The treatment landscape for castration-resistant prostate cancer (mCRPC) is undergoing significant advancements, particularly with the emergence of poly(ADP-ribose) polymerase inhibitors and their recent US FDA authorizations. The combination of olaparib with abiraterone and prednisone/prednisolone has gained approval for mCRPC patients harboring confirmed BRCA mutations. Subsequently, talazoparib in combination with enzalutamide was approved for patients with mutations in homologous recombination repair genes. Nevertheless, emerging evidence suggests that these treatments may confer benefits irrespective of specific biomarkers. While the understanding of biomarkers in therapy selection for mCRPC is expanding, further data are warranted to provide comprehensive elucidation for guiding clinical practice.

Tweetable abstract

How to determine the MAGNITUDE of benefit from poly(ADP-ribose) polymerase inhibitors? Ongoing debate on the utilization of biomarkers.

Keywords::

• BRCA1
• BRCA2
• castration-resistant
• DNA damage repair
• homologous recombination repair
• PARP inhibitors
• prostate cancer

Author contributions

Both authors participated in development of the manuscript, contributed to revising the draft manuscript and read and approved the final manuscript.

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

Competing interests disclosure

Advisory boards: Y Ürün has served on the advisory board for Abdi-İbrahim, Astellas, AstraZeneca, Bristol Myers Squibb, Eczacıbaşı, Gilead, Janssen, Merck, Novartis, Pfizer and Roche. Consultancy: Y Ürün received honoraria or has served as a consultant for Abdi-İbrahim, Astellas, Bristol Myers Squibb, Eczacıbaşı, Janssen, Merck, Novartis, Pfizer and Roche. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.